news on 08 April 2010 ...........
Sanofi-Aventis ups its fight for diabetes crown with licensing deal
Sanofi-Aventis could pay up to $335 million for CureDM's preclinical novel human peptide Pancreate, a potential treatment for types 1 and 2 diabetes.
CureDM, a US-based private biopharmaceutical company, has granted Sanofi-Aventis an exclusive global licence to develop, manufacture and commercialises...
ends.........
POH is in a far more advanced stage of Insulin evolution and if Sanofi is agreeing to pay up to $ 335M (That's about $ 0.50 per POH share) for a preclinical trial then a POH enhanced Insulpatch style product is worth an absolute Motza.
These guys at Southern Cross have just made a bucket load of money.
sanofi to pay up to $ 335m
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 55 | 89268918 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 59834650 | 19 |
View Market Depth
| Last trade - 16.12pm 29/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable